Sign In
Buy ANGO
$12.37
-0.0200 (-0.161%)
At Close: Jun 23, 2026
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now
02:11pm, Tuesday, 23'rd Jun 2026
ANGO's NanoKnife growth, strong Med Tech momentum and solid Q3 results support holding the stock despite tariff and inflation pressures.
ANGO Gains FDA IDE Approval for NanoKnife BPH Feasibility Study
10:55am, Thursday, 18'th Jun 2026
AngioDynamics' FDA IDE approval for RELIEF advances NanoKnife IRE study as a potential minimally invasive BPH treatment.
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment option
AngioDynamics, Inc. (ANGO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
12:12pm, Wednesday, 10'th Jun 2026
AngioDynamics, Inc. (ANGO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect
01:25pm, Thursday, 28'th May 2026
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment option
AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
08:30am, Wednesday, 27'th May 2026
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand
Wall Street Analysts See a 50.5% Upside in AngioDynamics (ANGO): Can the Stock Really Move This High?
10:56am, Friday, 22'nd May 2026
The mean of analysts' price targets for AngioDynamics (ANGO) points to a 50.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among an
Reasons to Add AngioDynamics Stock to Your Portfolio for Now
12:50pm, Tuesday, 19'th May 2026
ANGO gains momentum as NanoKnife adoption, strong Med Tech growth and positive clinical trends support its long-term outlook.
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment option
Wall Street Analysts Think AngioDynamics (ANGO) Could Surge 64.23%: Read This Before Placing a Bet
10:56am, Wednesday, 06'th May 2026
The mean of analysts' price targets for AngioDynamics (ANGO) points to a 64.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among an
AngioDynamics, Inc. (NASDAQ:ANGO) Given Consensus Recommendation of “Moderate Buy” by Analysts
04:24am, Thursday, 23'rd Apr 2026
AngioDynamics, Inc. (NASDAQ: ANGO - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the six analysts that are covering the company, MarketBeat.com reports. One inv
Wall Street Analysts Believe AngioDynamics (ANGO) Could Rally 65.75%: Here's is How to Trade
10:56am, Monday, 20'th Apr 2026
The average of price targets set by Wall Street analysts indicates a potential upside of 65.8% in AngioDynamics (ANGO). While the effectiveness of this highly sought-after metric is questionable, the
AngioDynamics (ANGO) Loses 5.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:36am, Friday, 10'th Apr 2026
The heavy selling pressure might have exhausted for AngioDynamics (ANGO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analy
AngioDynamics (ANGO) Upgraded to Buy: Here's Why
01:00pm, Wednesday, 08'th Apr 2026
AngioDynamics (ANGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ANGO Stock Up in Pre-Market Post Q3 Earnings Beat, Gross Margin Down
01:17pm, Monday, 06'th Apr 2026
AngioDynamics tops estimates as revenue rises and losses narrow, driven by Med Tech demand, even as gross margin slips.
